Literature DB >> 15265509

Kinetics of degradation and oil solubility of ester prodrugs of a model dipeptide (Gly-Phe).

Susan Weng Larsen1, Michael Ankersen, Claus Larsen.   

Abstract

Oil-based depot formulations may constitute a future delivery method for small peptides. Thus, a requirement is attainment of sufficient oil solubility for such active compounds. A model dipeptide (Gly-Phe) has been converted into lipophilic prodrugs by esterification at the C-terminal carboxylic acid group. The decomposition kinetics of octyl ester of Gly-Phe (IV) has been investigated at pH 7.4 (37 degrees C) and IV was shown to degrade by first-order kinetics via two parallel pathways (1) intramolecular aminolysis resulting in formation of a 2,5-diketopiperazine and (2) hydrolysis of the ester bond producing the dipeptide. The cyclisation reaction was dominating in the decomposition of methyl (II) butyl (III) octyl (IV) decyl (V) and dodecyl (VI) esters of Gly-Phe at pH 7.4. However, this degradation pathway was almost negligible for pH below 6. During degradation of the dipeptide esters in 80% human plasma pH 7.4 (37 degrees C) a minimal amount of cyclo(-Gly-Phe) was formed. A faster degradation of the esters in 80% human plasma pH 7.4 compared to those in aqueous solution pH 7.4 was suggested to be due to fast cleavage of the peptide bond. Low oil solubilities for Gly-Phe and the hydrochlorides of the dipeptide esters III and VI were observed. Although the solubility of Gly-Phe in oil solutions was enhanced by hydrophobic ion pairing with sodium decyl sulfonate the oil solubility was still less than 1 mg Gly-Phe/ml. By addition of a solubiliser, 10% N,N-dimethylacetamide (DMA), to Viscoleo the solubility of the HIP complexes increased significantly. The present study indicates that sufficient oil solubility might only be obtained for relatively small peptides by using the prodrug approach in combination with solubility enhancing organic solvents like DMA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265509     DOI: 10.1016/j.ejps.2004.04.013

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  7 in total

Review 1.  Cyclization-activated prodrugs.

Authors:  Paula Gomes; Nuno Vale; Rui Moreira
Journal:  Molecules       Date:  2007-11-12       Impact factor: 4.411

Review 2.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

3.  Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Pharm Res       Date:  2011-06-14       Impact factor: 4.200

4.  Dipeptide Prodrugs of the Glutamate Modulator Riluzole.

Authors:  Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz
Journal:  ACS Med Chem Lett       Date:  2018-06-15       Impact factor: 4.345

5.  Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.

Authors:  Yasuhiro Tsume; Adam J Drelich; David E Smith; Gordon L Amidon
Journal:  Molecules       Date:  2017-08-10       Impact factor: 4.411

6.  Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

Authors:  Yasuhiro Tsume; John M Hilfinger; Gordon L Amidon
Journal:  Mol Pharm       Date:  2008-07-25       Impact factor: 4.939

7.  Prediction and analysis of protein solubility using a novel scoring card method with dipeptide composition.

Authors:  Hui-Ling Huang; Phasit Charoenkwan; Te-Fen Kao; Hua-Chin Lee; Fang-Lin Chang; Wen-Lin Huang; Shinn-Jang Ho; Li-Sun Shu; Wen-Liang Chen; Shinn-Ying Ho
Journal:  BMC Bioinformatics       Date:  2012-12-13       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.